Market Overview

Credit Suisse Raises Eli Lilly Price Target

Related LLY
Mid-Afternoon Market Update: Crude Oil Down 2.5%; Gigamon Shares Drop After Issuing Lower Forecast
15 Biggest Mid-Day Gainers For Wednesday
The Vetr community has upgraded $LLY to 3-Stars. (Vetr)

Here are three takeaways on Credit Suiss's price target increase of Eli Lilly and Co (NYSE: LLY).

"1. We raise our target price to $65 (from $61).

2. Raising TP Following 3Q 2014, Remain Neutral While Watching Commercial Execution

3. We maintain our Neutral rating on the stock given the stock’s current valuation and look for successful commercial execution of new product launches, most notably Trulicity (dulaglutide)."

Shares of Eli lilly were up fractionally on average volume at $66.48.

Benzinga Color is embargoed from Benzinga Pro. The content above is delayed by 1.5 hours.

To get it live, subscribe to Benzinga Pro.

Latest Ratings for LLY

Dec 2016Morgan StanleyUpgradesEqual-WeightOverweight
Nov 2016BMO CapitalDowngradesOutperformMarket Perform
Nov 2016Atlantic EquitiesDowngradesOverweightNeutral

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Price Target Analyst Ratings


Related Articles (LLY)

View Comments and Join the Discussion!